AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

We recently compiled a list of the 10 Best UK Stocks to Invest in Now. In this article, we are going to take a look at where ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe ...

The AstraZeneca PLC ADR AZN inched 0.01% higher to $71.43 Monday, on what proved to be an all-around grim trading session for ...

AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety ...

AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a disorder characterised by ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report). The company’s ...

According to a study by Coherent market Insights, and is expected to grow at a CAGR of 11.3% in terms of revenue over the forecast period (2024-2031). Mr. Shah Coherent Market Insights Pvt. Ltd. +1 ...

AstraZeneca PLC, maintaining its operations in China, remains steadfast amidst speculative media scrutiny concerning ongoing ...

AstraZeneca and Eccogene presented early data from trials on ECC5004 for obesity, showing consistent safety and tolerability. In trials, ECC5004 displayed a linear PK profile and was unaffected by ...